USFDA inspection cited eight procedural issues at Aurobindo Pharma; the company assured no financial impact, response is planned soon.

• Inspection covered oral solids and injectables between 25 August and 5 September 2025, ending with eight procedural USFDA observations.
• Aurobindo confirmed observations are procedural, stressing no impact on financials or operations, with a response to be submitted shortly.
• The company reiterated its global commitment to maintaining strict quality standards in manufacturing active pharmaceutical ingredients, generics, and related healthcare services.